133 related articles for article (PubMed ID: 16896507)
1. Reduction in the risk of developing back pain persists at least 30 months after discontinuation of teriparatide treatment: a meta-analysis.
Nevitt MC; Chen P; Kiel DP; Reginster JY; Dore RK; Zanchetta JR; Glass EV; Krege JH
Osteoporos Int; 2006; 17(11):1630-7. PubMed ID: 16896507
[TBL] [Abstract][Full Text] [Related]
2. Reduced risk of back pain following teriparatide treatment: a meta-analysis.
Nevitt MC; Chen P; Dore RK; Reginster JY; Kiel DP; Zanchetta JR; Glass EV; Krege JH
Osteoporos Int; 2006 Feb; 17(2):273-80. PubMed ID: 16142502
[TBL] [Abstract][Full Text] [Related]
3. Fracture rate and back pain during and after discontinuation of teriparatide: 36-month data from the European Forsteo Observational Study (EFOS).
Fahrleitner-Pammer A; Langdahl BL; Marin F; Jakob F; Karras D; Barrett A; Ljunggren Ö; Walsh JB; Rajzbaum G; Barker C; Lems WF
Osteoporos Int; 2011 Oct; 22(10):2709-19. PubMed ID: 21113576
[TBL] [Abstract][Full Text] [Related]
4. Back pain treatment in post-menopausal osteoporosis with vertebral fractures.
Ulivieri FM
Aging Clin Exp Res; 2007 Jun; 19(3 Suppl):21-3. PubMed ID: 18180603
[TBL] [Abstract][Full Text] [Related]
5. The effects of teriparatide on the incidence of back pain in postmenopausal women with osteoporosis.
Genant HK; Halse J; Briney WG; Xie L; Glass EV; Krege JH
Curr Med Res Opin; 2005 Jul; 21(7):1027-34. PubMed ID: 16004669
[TBL] [Abstract][Full Text] [Related]
6. Longterm reduction of back pain risk in women with osteoporosis treated with teriparatide compared with alendronate.
Miller PD; Shergy WJ; Body JJ; Chen P; Rohe ME; Krege JH
J Rheumatol; 2005 Aug; 32(8):1556-62. PubMed ID: 16078334
[TBL] [Abstract][Full Text] [Related]
7. Reduction in vertebral fracture risk in teriparatide-treated postmenopausal women as assessed by spinal deformity index.
Genant HK; Siris E; Crans GG; Desaiah D; Krege JH
Bone; 2005 Aug; 37(2):170-4. PubMed ID: 15961357
[TBL] [Abstract][Full Text] [Related]
8. Treatment persistence and changes in fracture risk, back pain, and quality of life amongst patients treated with teriparatide in routine clinical care in France: results from the European Forsteo Observational Study.
Rajzbaum G; Grados F; Evans D; Liu-Leage S; Petto H; Augendre-Ferrante B
Joint Bone Spine; 2014 Jan; 81(1):69-75. PubMed ID: 23796729
[TBL] [Abstract][Full Text] [Related]
9. Study description and baseline characteristics of the population enrolled in a multinational observational study of extended teriparatide use (ExFOS).
Ljunggren O; Benhamou CL; Dekker J; Kapetanos G; Kocjan T; Langdahl BL; Napoli N; Petto H; Nikolić T; Lindh E
Curr Med Res Opin; 2014 Aug; 30(8):1607-16. PubMed ID: 24720366
[TBL] [Abstract][Full Text] [Related]
10. Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy.
Kaufman JM; Orwoll E; Goemaere S; San Martin J; Hossain A; Dalsky GP; Lindsay R; Mitlak BH
Osteoporos Int; 2005 May; 16(5):510-6. PubMed ID: 15322742
[TBL] [Abstract][Full Text] [Related]
11. Teriparatide use during an economic crisis: baseline data from the Greek cohort of the Extended Forsteo Observational Study (ExFOS).
Aloumanis K; Kapetanos G; Bartzis N; Drossinos V;
BMC Musculoskelet Disord; 2015 Jun; 16():136. PubMed ID: 26044820
[TBL] [Abstract][Full Text] [Related]
12. Relationship between duration of teriparatide therapy and clinical outcomes in postmenopausal women with osteoporosis.
Lindsay R; Miller P; Pohl G; Glass EV; Chen P; Krege JH
Osteoporos Int; 2009 Jun; 20(6):943-8. PubMed ID: 18923884
[TBL] [Abstract][Full Text] [Related]
13. Sustained nonvertebral fragility fracture risk reduction after discontinuation of teriparatide treatment.
Prince R; Sipos A; Hossain A; Syversen U; Ish-Shalom S; Marcinowska E; Halse J; Lindsay R; Dalsky GP; Mitlak BH
J Bone Miner Res; 2005 Sep; 20(9):1507-13. PubMed ID: 16059622
[TBL] [Abstract][Full Text] [Related]
14. Fracture Rate, Quality of Life and Back Pain in Patients with Osteoporosis Treated with Teriparatide: 24-Month Results from the Extended Forsteo Observational Study (ExFOS).
Langdahl BL; Ljunggren Ö; Benhamou CL; Marin F; Kapetanos G; Kocjan T; Lespessailles E; Napoli N; Nikolic T; Petto H; Moll T; Lindh E
Calcif Tissue Int; 2016 Sep; 99(3):259-71. PubMed ID: 27137783
[TBL] [Abstract][Full Text] [Related]
15. Randomized Teriparatide [human parathyroid hormone (PTH) 1-34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk.
Nakamura T; Sugimoto T; Nakano T; Kishimoto H; Ito M; Fukunaga M; Hagino H; Sone T; Yoshikawa H; Nishizawa Y; Fujita T; Shiraki M
J Clin Endocrinol Metab; 2012 Sep; 97(9):3097-106. PubMed ID: 22723322
[TBL] [Abstract][Full Text] [Related]
16. Teriparatide and raloxifene reduce the risk of new adjacent vertebral fractures in postmenopausal women with osteoporosis. Results from two randomized controlled trials.
Bouxsein ML; Chen P; Glass EV; Kallmes DF; Delmas PD; Mitlak BH
J Bone Joint Surg Am; 2009 Jun; 91(6):1329-38. PubMed ID: 19487509
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of teriparatide in postmenopausal women with osteoporosis and glucocorticoid use: 3-year results from the EFOS study.
Karras D; Stoykov I; Lems WF; Langdahl BL; Ljunggren Ö; Barrett A; Walsh JB; Fahrleitner-Pammer A; Rajzbaum G; Jakob F; Marin F
J Rheumatol; 2012 Mar; 39(3):600-9. PubMed ID: 22247365
[TBL] [Abstract][Full Text] [Related]
18. Effects of Teriparatide in Patients with Osteoporosis in Clinical Practice: 42-Month Results During and After Discontinuation of Treatment from the European Extended Forsteo® Observational Study (ExFOS).
Napoli N; Langdahl BL; Ljunggren Ö; Lespessailles E; Kapetanos G; Kocjan T; Nikolic T; Eiken P; Petto H; Moll T; Lindh E; Marin F
Calcif Tissue Int; 2018 Oct; 103(4):359-371. PubMed ID: 29909449
[TBL] [Abstract][Full Text] [Related]
19. Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis.
Lindsay R; Scheele WH; Neer R; Pohl G; Adami S; Mautalen C; Reginster JY; Stepan JJ; Myers SL; Mitlak BH
Arch Intern Med; 2004 Oct; 164(18):2024-30. PubMed ID: 15477438
[TBL] [Abstract][Full Text] [Related]
20. Change in lumbar spine BMD and vertebral fracture risk reduction in teriparatide-treated postmenopausal women with osteoporosis.
Chen P; Miller PD; Delmas PD; Misurski DA; Krege JH
J Bone Miner Res; 2006 Nov; 21(11):1785-90. PubMed ID: 17002571
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]